Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.

Dementia and geriatric cognitive disorders - 1 Jan 2000

Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W

Abstract excerpt

Apolipoprotein E (APOE) has been extensively demonstrated to be a genetic risk factor for Alzheimer's disease (AD). Associations of APOE genotype have been reported with age at AD onset, rate of decline, and responsiveness to therapy. This study aimed to test these hypotheses in a large study population of AD patients. APOE genotype was determined from 1,528 Caucasian subjects, diagnosed by NINCDS/ADRDA criteria...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoproteins E
Share to Cognition Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Fragmentation

Share to Double-Blind Method

Share to Neuropsychological Tests

Share to Piperidines

Share to Randomized Controlled Trials as Topic

Share to Thiazoles

Source

Identifiers

PMID: 11173877
DOI: 10.1159/000051238

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.PMID 11173877Read ↗

Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.Semantic proximity Read ↗

Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.Semantic proximity Read ↗

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease.Semantic proximity Read ↗

Alzheimer's disease: clinical implications of the apolipoprotein E genotype.Semantic proximity Read ↗

Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.Semantic proximity Read ↗

The APOE genotype: modification of therapeutic responses in Alzheimer's disease.Semantic proximity Read ↗

Apolipoprotein E genotype and gender influence response to tacrine therapy.Semantic proximity Read ↗

No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease.Semantic proximity Read ↗

Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease.Semantic proximity Read ↗

The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease.Semantic proximity Read ↗

BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.Semantic proximity Read ↗

Effect of <i>APOE</i> genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.